XXI. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene 
Therapy Protocol Entitled: Immunization of Malignant Melanoma Patients 
with Interleukin-2 Secreting Melanoma Cells Expressing Defined 
Allogeneic Histocompatibility Antigens /Dts. Das Gupta, Cohen and 
Richards 40 
xxn. Addition of Appendix D of the NIH Guidelines Regarding a Human Gene 
Therapy Protocol Entitled: Human MDR Gene Transfer in Patients with 
Advanced Cancer /Drs. Hesdorffer and Antman 42 
XXIII. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene 
Therapy Protocol Entitled: Gene Therapy for Human Brain Tumors Using 
Episome-Based Antisense cDNA Transcription of Insulin-like Growth 
Factor /Dr. Ilan 45 
XXIV. Addition to Appendix D of the NIH Guidelines Regarding a Semliki 
Forest Virus (SFV) Vector Expression System-Reduction of Physical 
Containment from BL3 to BL2/Dr. Temple 47 
XXV. Addition to Appendix D of the NIH Guidelines Regarding The Poxvirus 
Vectors NYVAC, ALVAC and TROF>lC-Reduction of Physical Containment 
From BL2 to BLl/Dr. Paoletti 50 
XXVI. Report from the Working Group on Exempt Review of Human Gene Transfer 
Protocols/Dr. Parkman 52 
XXVTI. A Draft Letter to the NIH Director Regarding Compensation for Research- 
Related Injuries 52 
XXVIII. Adjournment 53 
Attachments 
I. Roster 
II. Data Management Report 
III. Minor Modifications Report 
[542] 
Recombinant DNA Research, Volume 17 
